Nov 20, 2020 7:30am EST Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day
Nov 19, 2020 9:00am EST Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
Nov 09, 2020 3:18pm EST Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
Oct 22, 2020 8:00am EDT Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020
Oct 15, 2020 4:40pm EDT Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
Aug 28, 2020 10:30am EDT Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients
Jul 23, 2020 4:00pm EDT Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
